imatinib mesylate has been researched along with Cancer of Pelvis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akan, S; Ürkmez, A; Verit, A; Yildirim, Ç; Yüksel, ÖH | 1 |
| Hirasawa, T; Iida, T; Kajiwara, H; Kikuchi, K; Mikami, M; Murakami, M; Muramatsu, T; Osamura, RY; Yamashita, E; Yasuda, M; Yasuda, S; Yasui, I | 1 |
| Hanai, K; Hoshi, A; Kato, S; Kawakami, M; Kim, H; Nakajima, N; Nomoto, T; Sadahiro, S; Shinozaki, T; Soeda, S; Terachi, T; Usui, Y | 1 |
1 review(s) available for imatinib mesylate and Cancer of Pelvis
| Article | Year |
|---|---|
Extraintestinal gastrointestinal stromal tumor of undetermined origin: Is the mass resection a wrong approach? A case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Pelvic Neoplasms; Piperazines; Postoperative Care; Prostatectomy; Prostatic Neoplasms; Pyrimidines; Treatment Outcome | 2015 |
2 other study(ies) available for imatinib mesylate and Cancer of Pelvis
| Article | Year |
|---|---|
A resectable case of gastrointestinal stromal tumor derived from the rectal wall after oral targeted molecular therapy with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Middle Aged; Molecular Targeted Therapy; Pelvic Neoplasms; Piperazines; Pyrimidines; Rectum; Treatment Outcome | 2006 |
[Successful resection of a gastrointestinal stromal tumor in the pelvis with imatinib mesylate as neoadjuvant therapy].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoadjuvant Therapy; Pelvic Neoplasms; Piperazines; Pyrimidines; Treatment Outcome | 2011 |